organization · Reporting owner
ICS OPPORTUNITIES II LLC
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Faeth Therapeutics, Inc.
Report date April 02, 2026 · Filed May 15, 2026
Jointly reported with MILLENNIUM MANAGEMENT LLC, MILLENNIUM GROUP MANAGEMENT LLC, ENGLANDER ISRAEL A
Section 16 reporting ended · disclosed 2026-05-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 144,974 |
Reported balance
After 2026-04-02 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2026-04-02 · Purchase · Acquired 26 · Balance 144,974 F1: Represents volume-weighted average price ("VWAP") of purchases of 26 shares of common stock ("Common Stock"), par value $0.0001 per share, of Sensei Biotherapeutics, Inc. (the "Company") on April 2, 2026 at prices ranging from $32.90 to $33.62. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting persons will provide full information regarding the number of shares purchased or sold by the reporting person at each separate price within each range represented by a VWAP disclosed herein. F2: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 144,974 |
Reported balance
After 2026-04-02 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2026-04-02 · Purchase · Acquired 1,276 · Balance 144,974 F4: Represents VWAP of purchases of 1,276 shares of the Company's Common Stock on April 2, 2026 at prices ranging from $33.97 to $34.90. F2: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 144,974 |
Reported balance
After 2026-04-02 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2026-04-02 · Purchase · Acquired 701 · Balance 144,974 F5: Represents VWAP of purchases of 701 shares of the Company's Common Stock on April 2, 2026 at prices ranging from $35.4481 to $35.91. F2: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 144,974 |
Reported balance
After 2026-04-02 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2026-04-02 · Sale · Disposed 3,099 · Balance 144,974 F6: Represents VWAP of sales of 3,099 shares of the Company's Common Stock on April 2, 2026 at prices ranging from $30.1332 to $31.1212. F2: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 144,974 |
Reported balance
After 2026-04-02 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2026-04-02 · Sale · Disposed 1,265 · Balance 144,974 F7: Represents VWAP of sales of 1,265 shares of the Company's Common Stock on April 2, 2026 at prices ranging from $31.21 to $32.15. F2: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 144,974 |
Reported balance
After 2026-04-02 transaction · row 6
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 6 · 2026-04-02 · Sale · Disposed 1,794 · Balance 144,974 F8: Represents VWAP of sales of 1,794 shares of the Company's Common Stock on April 2, 2026 at prices ranging from $32.22 to $33.1251. F2: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 144,974 |
Reported balance
After 2026-04-02 transaction · row 7
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 7 · 2026-04-02 · Sale · Disposed 374 · Balance 144,974 F9: Represents VWAP of sales of 374 shares of the Company's Common Stock on April 2, 2026 at prices ranging from $33.23 to $33.45. F2: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 144,974 |
Reported balance
After 2026-04-02 transaction · row 8
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 8 · 2026-04-02 · Sale · Disposed 1,134 · Balance 144,974 F10: Represents VWAP of sales of 1,134 shares of the Company's Common Stock on April 2, 2026 at prices ranging from $34.40 to $35.25. F2: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 141,029 |
Reported balance
After 2026-04-06 transaction · row 9
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 9 · 2026-04-06 · Purchase · Acquired 1,104 · Balance 141,029 F11: Represents purchases of 1,104 shares of the Company's Common Stock on April 6, 2026 at $31.02 per share. F2: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 141,029 |
Reported balance
After 2026-04-06 transaction · row 10
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 10 · 2026-04-06 · Sale · Disposed 1,214 · Balance 141,029 F12: Represents VWAP of sales of 1,214 shares of the Company's Common Stock on April 6, 2026 at prices ranging from $30.64 to $31.345. F2: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 141,029 |
Reported balance
After 2026-04-06 transaction · row 11
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 11 · 2026-04-06 · Sale · Disposed 45 · Balance 141,029 F13: Represents VWAP of sales of 45 shares of the Company's Common Stock on April 6, 2026 at prices ranging from $31.80 to $32.17. F2: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 133,986 |
Reported balance
After 2026-04-07 transaction · row 12
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 12 · 2026-04-07 · Purchase · Acquired 1,108 · Balance 133,986 F14: Represents VWAP of purchases of 1,108 shares of the Company's Common Stock on April 7, 2026 at $33.38 per share. F2: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 133,986 |
Reported balance
After 2026-04-07 transaction · row 13
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 13 · 2026-04-07 · Sale · Disposed 2,115 · Balance 133,986 F15: Represents VWAP of sales of 2,115 shares of the Company's Common Stock on April 7, 2026 at prices ranging from $28.5071 to $29.3167. F2: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 133,986 |
Reported balance
After 2026-04-07 transaction · row 14
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 14 · 2026-04-07 · Sale · Disposed 205 · Balance 133,986 F16: Represents VWAP of sales of 205 shares of the Company's Common Stock on April 7, 2026 at prices ranging from $29.695 to $30.50. F2: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 133,986 |
Reported balance
After 2026-04-07 transaction · row 15
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 15 · 2026-04-07 · Sale · Disposed 4,423 · Balance 133,986 F17: Represents VWAP of sales of 4,423 shares of the Company's Common Stock on April 7, 2026 at prices ranging from $30.9852 to $31.813. F2: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 133,986 |
Reported balance
After 2026-04-07 transaction · row 16
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 16 · 2026-04-07 · Sale · Disposed 300 · Balance 133,986 F18: Represents VWAP of sales of 300 shares of the Company's Common Stock on April 7, 2026 at prices ranging from $32.0625 to $32.615. F2: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 133,986 |
Reported balance
After 2026-04-07 transaction · row 17
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 17 · 2026-04-07 · Sale · Disposed 1,108 · Balance 133,986 F19: Represents sales of 1,108 shares of the Company's Common Stock on April 7, 2026 at $33.38 per share. F2: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents volume-weighted average price ("VWAP") of purchases of 26 shares of common stock ("Common Stock"), par value $0.0001 per share, of Sensei Biotherapeutics, Inc. (the "Company") on April 2, 2026 at prices ranging from $32.90 to $33.62. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting persons will provide full information regarding the number of shares purchased or sold by the reporting person at each separate price within each range represented by a VWAP disclosed herein.
F2: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2.
F3: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any.
F4: Represents VWAP of purchases of 1,276 shares of the Company's Common Stock on April 2, 2026 at prices ranging from $33.97 to $34.90.
F5: Represents VWAP of purchases of 701 shares of the Company's Common Stock on April 2, 2026 at prices ranging from $35.4481 to $35.91.
F6: Represents VWAP of sales of 3,099 shares of the Company's Common Stock on April 2, 2026 at prices ranging from $30.1332 to $31.1212.
F7: Represents VWAP of sales of 1,265 shares of the Company's Common Stock on April 2, 2026 at prices ranging from $31.21 to $32.15.
F8: Represents VWAP of sales of 1,794 shares of the Company's Common Stock on April 2, 2026 at prices ranging from $32.22 to $33.1251.
F9: Represents VWAP of sales of 374 shares of the Company's Common Stock on April 2, 2026 at prices ranging from $33.23 to $33.45.
F10: Represents VWAP of sales of 1,134 shares of the Company's Common Stock on April 2, 2026 at prices ranging from $34.40 to $35.25.
F11: Represents purchases of 1,104 shares of the Company's Common Stock on April 6, 2026 at $31.02 per share.
F12: Represents VWAP of sales of 1,214 shares of the Company's Common Stock on April 6, 2026 at prices ranging from $30.64 to $31.345.
F13: Represents VWAP of sales of 45 shares of the Company's Common Stock on April 6, 2026 at prices ranging from $31.80 to $32.17.
F14: Represents VWAP of purchases of 1,108 shares of the Company's Common Stock on April 7, 2026 at $33.38 per share.
F15: Represents VWAP of sales of 2,115 shares of the Company's Common Stock on April 7, 2026 at prices ranging from $28.5071 to $29.3167.
F16: Represents VWAP of sales of 205 shares of the Company's Common Stock on April 7, 2026 at prices ranging from $29.695 to $30.50.
F17: Represents VWAP of sales of 4,423 shares of the Company's Common Stock on April 7, 2026 at prices ranging from $30.9852 to $31.813.
F18: Represents VWAP of sales of 300 shares of the Company's Common Stock on April 7, 2026 at prices ranging from $32.0625 to $32.615.
F19: Represents sales of 1,108 shares of the Company's Common Stock on April 7, 2026 at $33.38 per share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 07, 2026 Filed May 15, 2026 20:24 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | SaleCommon Stock | 1,108 | $33.38 | $36,985.04 |
DisclosureSEC source: 0001104659-26-062608 · tm2614687-4_4seq1.xml · nonDerivative · entry 17 MILLENNIUM MANAGEMENT LLC · CIK 0001273087 · 10% owner ICS OPPORTUNITIES II LLC · CIK 0001783647 · 10% owner MILLENNIUM GROUP MANAGEMENT LLC · CIK 0001446830 · 10% owner ENGLANDER ISRAEL A · CIK 0001017456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 133,986 F19 · price: Represents sales of 1,108 shares of the Company's Common Stock on April 7, 2026 at $33.38 per share. F2 · balance_after: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3 · ownership.nature: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. Read SEC document |
| April 07, 2026 Filed May 15, 2026 20:24 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | SaleCommon Stock | 300 | $32.25 | $9,674.01 |
DisclosureSEC source: 0001104659-26-062608 · tm2614687-4_4seq1.xml · nonDerivative · entry 16 MILLENNIUM MANAGEMENT LLC · CIK 0001273087 · 10% owner ICS OPPORTUNITIES II LLC · CIK 0001783647 · 10% owner MILLENNIUM GROUP MANAGEMENT LLC · CIK 0001446830 · 10% owner ENGLANDER ISRAEL A · CIK 0001017456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 133,986 F18 · price: Represents VWAP of sales of 300 shares of the Company's Common Stock on April 7, 2026 at prices ranging from $32.0625 to $32.615. F2 · balance_after: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3 · ownership.nature: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. Read SEC document |
| April 07, 2026 Filed May 15, 2026 20:24 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | SaleCommon Stock | 4,423 | $31.38 | $138,812.76 |
DisclosureSEC source: 0001104659-26-062608 · tm2614687-4_4seq1.xml · nonDerivative · entry 15 MILLENNIUM MANAGEMENT LLC · CIK 0001273087 · 10% owner ICS OPPORTUNITIES II LLC · CIK 0001783647 · 10% owner MILLENNIUM GROUP MANAGEMENT LLC · CIK 0001446830 · 10% owner ENGLANDER ISRAEL A · CIK 0001017456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 133,986 F17 · price: Represents VWAP of sales of 4,423 shares of the Company's Common Stock on April 7, 2026 at prices ranging from $30.9852 to $31.813. F2 · balance_after: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3 · ownership.nature: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. Read SEC document |
| April 07, 2026 Filed May 15, 2026 20:24 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | SaleCommon Stock | 205 | $29.71 | $6,091.49 |
DisclosureSEC source: 0001104659-26-062608 · tm2614687-4_4seq1.xml · nonDerivative · entry 14 MILLENNIUM MANAGEMENT LLC · CIK 0001273087 · 10% owner ICS OPPORTUNITIES II LLC · CIK 0001783647 · 10% owner MILLENNIUM GROUP MANAGEMENT LLC · CIK 0001446830 · 10% owner ENGLANDER ISRAEL A · CIK 0001017456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 133,986 F16 · price: Represents VWAP of sales of 205 shares of the Company's Common Stock on April 7, 2026 at prices ranging from $29.695 to $30.50. F2 · balance_after: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3 · ownership.nature: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. Read SEC document |
| April 07, 2026 Filed May 15, 2026 20:24 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | SaleCommon Stock | 2,115 | $28.94 | $61,211.70 |
DisclosureSEC source: 0001104659-26-062608 · tm2614687-4_4seq1.xml · nonDerivative · entry 13 MILLENNIUM MANAGEMENT LLC · CIK 0001273087 · 10% owner ICS OPPORTUNITIES II LLC · CIK 0001783647 · 10% owner MILLENNIUM GROUP MANAGEMENT LLC · CIK 0001446830 · 10% owner ENGLANDER ISRAEL A · CIK 0001017456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 133,986 F15 · price: Represents VWAP of sales of 2,115 shares of the Company's Common Stock on April 7, 2026 at prices ranging from $28.5071 to $29.3167. F2 · balance_after: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3 · ownership.nature: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. Read SEC document |
| April 07, 2026 Filed May 15, 2026 20:24 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | PurchaseCommon Stock | 1,108 | $33.38 | $36,985.04 |
DisclosureSEC source: 0001104659-26-062608 · tm2614687-4_4seq1.xml · nonDerivative · entry 12 MILLENNIUM MANAGEMENT LLC · CIK 0001273087 · 10% owner ICS OPPORTUNITIES II LLC · CIK 0001783647 · 10% owner MILLENNIUM GROUP MANAGEMENT LLC · CIK 0001446830 · 10% owner ENGLANDER ISRAEL A · CIK 0001017456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 133,986 F14 · price: Represents VWAP of purchases of 1,108 shares of the Company's Common Stock on April 7, 2026 at $33.38 per share. F2 · balance_after: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3 · ownership.nature: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. Read SEC document |
| April 06, 2026 Filed May 15, 2026 20:24 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | SaleCommon Stock | 45 | $31.96 | $1,438.33 |
DisclosureSEC source: 0001104659-26-062608 · tm2614687-4_4seq1.xml · nonDerivative · entry 11 MILLENNIUM MANAGEMENT LLC · CIK 0001273087 · 10% owner ICS OPPORTUNITIES II LLC · CIK 0001783647 · 10% owner MILLENNIUM GROUP MANAGEMENT LLC · CIK 0001446830 · 10% owner ENGLANDER ISRAEL A · CIK 0001017456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 141,029 F13 · price: Represents VWAP of sales of 45 shares of the Company's Common Stock on April 6, 2026 at prices ranging from $31.80 to $32.17. F2 · balance_after: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3 · ownership.nature: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. Read SEC document |
| April 06, 2026 Filed May 15, 2026 20:24 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | SaleCommon Stock | 1,214 | $31.02 | $37,661.56 |
DisclosureSEC source: 0001104659-26-062608 · tm2614687-4_4seq1.xml · nonDerivative · entry 10 MILLENNIUM MANAGEMENT LLC · CIK 0001273087 · 10% owner ICS OPPORTUNITIES II LLC · CIK 0001783647 · 10% owner MILLENNIUM GROUP MANAGEMENT LLC · CIK 0001446830 · 10% owner ENGLANDER ISRAEL A · CIK 0001017456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 141,029 F12 · price: Represents VWAP of sales of 1,214 shares of the Company's Common Stock on April 6, 2026 at prices ranging from $30.64 to $31.345. F2 · balance_after: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3 · ownership.nature: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. Read SEC document |
| April 06, 2026 Filed May 15, 2026 20:24 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | PurchaseCommon Stock | 1,104 | $31.02 | $34,246.08 |
DisclosureSEC source: 0001104659-26-062608 · tm2614687-4_4seq1.xml · nonDerivative · entry 9 MILLENNIUM MANAGEMENT LLC · CIK 0001273087 · 10% owner ICS OPPORTUNITIES II LLC · CIK 0001783647 · 10% owner MILLENNIUM GROUP MANAGEMENT LLC · CIK 0001446830 · 10% owner ENGLANDER ISRAEL A · CIK 0001017456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 141,029 F11 · price: Represents purchases of 1,104 shares of the Company's Common Stock on April 6, 2026 at $31.02 per share. F2 · balance_after: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3 · ownership.nature: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. Read SEC document |
| April 02, 2026 Filed May 15, 2026 20:24 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | SaleCommon Stock | 1,134 | $34.80 | $39,463.99 |
DisclosureSEC source: 0001104659-26-062608 · tm2614687-4_4seq1.xml · nonDerivative · entry 8 MILLENNIUM MANAGEMENT LLC · CIK 0001273087 · 10% owner ICS OPPORTUNITIES II LLC · CIK 0001783647 · 10% owner MILLENNIUM GROUP MANAGEMENT LLC · CIK 0001446830 · 10% owner ENGLANDER ISRAEL A · CIK 0001017456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 144,974 F10 · price: Represents VWAP of sales of 1,134 shares of the Company's Common Stock on April 2, 2026 at prices ranging from $34.40 to $35.25. F2 · balance_after: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3 · ownership.nature: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. Read SEC document |
| April 02, 2026 Filed May 15, 2026 20:24 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | SaleCommon Stock | 374 | $33.35 | $12,471.78 |
DisclosureSEC source: 0001104659-26-062608 · tm2614687-4_4seq1.xml · nonDerivative · entry 7 MILLENNIUM MANAGEMENT LLC · CIK 0001273087 · 10% owner ICS OPPORTUNITIES II LLC · CIK 0001783647 · 10% owner MILLENNIUM GROUP MANAGEMENT LLC · CIK 0001446830 · 10% owner ENGLANDER ISRAEL A · CIK 0001017456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 144,974 F9 · price: Represents VWAP of sales of 374 shares of the Company's Common Stock on April 2, 2026 at prices ranging from $33.23 to $33.45. F2 · balance_after: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3 · ownership.nature: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. Read SEC document |
| April 02, 2026 Filed May 15, 2026 20:24 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | SaleCommon Stock | 1,794 | $32.60 | $58,491.76 |
DisclosureSEC source: 0001104659-26-062608 · tm2614687-4_4seq1.xml · nonDerivative · entry 6 MILLENNIUM MANAGEMENT LLC · CIK 0001273087 · 10% owner ICS OPPORTUNITIES II LLC · CIK 0001783647 · 10% owner MILLENNIUM GROUP MANAGEMENT LLC · CIK 0001446830 · 10% owner ENGLANDER ISRAEL A · CIK 0001017456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 144,974 F8 · price: Represents VWAP of sales of 1,794 shares of the Company's Common Stock on April 2, 2026 at prices ranging from $32.22 to $33.1251. F2 · balance_after: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3 · ownership.nature: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. Read SEC document |
| April 02, 2026 Filed May 15, 2026 20:24 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | SaleCommon Stock | 1,265 | $31.75 | $40,165.02 |
DisclosureSEC source: 0001104659-26-062608 · tm2614687-4_4seq1.xml · nonDerivative · entry 5 MILLENNIUM MANAGEMENT LLC · CIK 0001273087 · 10% owner ICS OPPORTUNITIES II LLC · CIK 0001783647 · 10% owner MILLENNIUM GROUP MANAGEMENT LLC · CIK 0001446830 · 10% owner ENGLANDER ISRAEL A · CIK 0001017456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 144,974 F7 · price: Represents VWAP of sales of 1,265 shares of the Company's Common Stock on April 2, 2026 at prices ranging from $31.21 to $32.15. F2 · balance_after: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3 · ownership.nature: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. Read SEC document |
| April 02, 2026 Filed May 15, 2026 20:24 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | SaleCommon Stock | 3,099 | $30.86 | $95,646.92 |
DisclosureSEC source: 0001104659-26-062608 · tm2614687-4_4seq1.xml · nonDerivative · entry 4 MILLENNIUM MANAGEMENT LLC · CIK 0001273087 · 10% owner ICS OPPORTUNITIES II LLC · CIK 0001783647 · 10% owner MILLENNIUM GROUP MANAGEMENT LLC · CIK 0001446830 · 10% owner ENGLANDER ISRAEL A · CIK 0001017456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 144,974 F6 · price: Represents VWAP of sales of 3,099 shares of the Company's Common Stock on April 2, 2026 at prices ranging from $30.1332 to $31.1212. F2 · balance_after: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3 · ownership.nature: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. Read SEC document |
| April 02, 2026 Filed May 15, 2026 20:24 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | PurchaseCommon Stock | 701 | $35.55 | $24,918.59 |
DisclosureSEC source: 0001104659-26-062608 · tm2614687-4_4seq1.xml · nonDerivative · entry 3 MILLENNIUM MANAGEMENT LLC · CIK 0001273087 · 10% owner ICS OPPORTUNITIES II LLC · CIK 0001783647 · 10% owner MILLENNIUM GROUP MANAGEMENT LLC · CIK 0001446830 · 10% owner ENGLANDER ISRAEL A · CIK 0001017456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 144,974 F5 · price: Represents VWAP of purchases of 701 shares of the Company's Common Stock on April 2, 2026 at prices ranging from $35.4481 to $35.91. F2 · balance_after: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3 · ownership.nature: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. Read SEC document |
| April 02, 2026 Filed May 15, 2026 20:24 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | PurchaseCommon Stock | 1,276 | $34.75 | $44,344.06 |
DisclosureSEC source: 0001104659-26-062608 · tm2614687-4_4seq1.xml · nonDerivative · entry 2 MILLENNIUM MANAGEMENT LLC · CIK 0001273087 · 10% owner ICS OPPORTUNITIES II LLC · CIK 0001783647 · 10% owner MILLENNIUM GROUP MANAGEMENT LLC · CIK 0001446830 · 10% owner ENGLANDER ISRAEL A · CIK 0001017456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 144,974 F4 · price: Represents VWAP of purchases of 1,276 shares of the Company's Common Stock on April 2, 2026 at prices ranging from $33.97 to $34.90. F2 · balance_after: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3 · ownership.nature: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. Read SEC document |
| April 02, 2026 Filed May 15, 2026 20:24 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | PurchaseCommon Stock | 26 | $33.47 | $870.23 |
DisclosureSEC source: 0001104659-26-062608 · tm2614687-4_4seq1.xml · nonDerivative · entry 1 MILLENNIUM MANAGEMENT LLC · CIK 0001273087 · 10% owner ICS OPPORTUNITIES II LLC · CIK 0001783647 · 10% owner MILLENNIUM GROUP MANAGEMENT LLC · CIK 0001446830 · 10% owner ENGLANDER ISRAEL A · CIK 0001017456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 144,974 F1 · price: Represents volume-weighted average price ("VWAP") of purchases of 26 shares of common stock ("Common Stock"), par value $0.0001 per share, of Sensei Biotherapeutics, Inc. (the "Company") on April 2, 2026 at prices ranging from $32.90 to $33.62. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting persons will provide full information regarding the number of shares purchased or sold by the reporting person at each separate price within each range represented by a VWAP disclosed herein. F2 · balance_after: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3 · ownership.nature: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. Read SEC document |
| April 01, 2026 Filed May 15, 2026 20:22 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | SaleCommon Stock | 46 | $34.75 | $1,598.33 |
DisclosureSEC source: 0001104659-26-062605 · tm2614687-3_4seq1.xml · nonDerivative · entry 17 MILLENNIUM MANAGEMENT LLC · CIK 0001273087 · 10% owner ICS OPPORTUNITIES II LLC · CIK 0001783647 · 10% owner MILLENNIUM GROUP MANAGEMENT LLC · CIK 0001446830 · 10% owner ENGLANDER ISRAEL A · CIK 0001017456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 147,731 F19 · price: Represents VWAP of sales of 46 shares of the Company's Common Stock on April 1, 2026 at prices ranging from $34.5271 to $35.3850. F2 · balance_after: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3 · ownership.nature: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. Read SEC document |
| April 01, 2026 Filed May 15, 2026 20:22 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | SaleCommon Stock | 1,104 | $31.52 | $34,798.08 |
DisclosureSEC source: 0001104659-26-062605 · tm2614687-3_4seq1.xml · nonDerivative · entry 16 MILLENNIUM MANAGEMENT LLC · CIK 0001273087 · 10% owner ICS OPPORTUNITIES II LLC · CIK 0001783647 · 10% owner MILLENNIUM GROUP MANAGEMENT LLC · CIK 0001446830 · 10% owner ENGLANDER ISRAEL A · CIK 0001017456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 147,731 F18 · price: Represents sales of 1,104 shares of the Company's Common Stock on April 1, 2026 at $31.52 per share. F2 · balance_after: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3 · ownership.nature: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. Read SEC document |
| April 01, 2026 Filed May 15, 2026 20:22 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | PurchaseCommon Stock | 3,401 | $35.46 | $120,583.82 |
DisclosureSEC source: 0001104659-26-062605 · tm2614687-3_4seq1.xml · nonDerivative · entry 15 MILLENNIUM MANAGEMENT LLC · CIK 0001273087 · 10% owner ICS OPPORTUNITIES II LLC · CIK 0001783647 · 10% owner MILLENNIUM GROUP MANAGEMENT LLC · CIK 0001446830 · 10% owner ENGLANDER ISRAEL A · CIK 0001017456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 147,731 F17 · price: Represents VWAP of purchases of 3,401 shares of the Company's Common Stock on April 1, 2026 at prices ranging from $35.06 to $35.90. F2 · balance_after: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3 · ownership.nature: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. Read SEC document |
| April 01, 2026 Filed May 15, 2026 20:22 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | PurchaseCommon Stock | 1,613 | $34.59 | $55,787.70 |
DisclosureSEC source: 0001104659-26-062605 · tm2614687-3_4seq1.xml · nonDerivative · entry 14 MILLENNIUM MANAGEMENT LLC · CIK 0001273087 · 10% owner ICS OPPORTUNITIES II LLC · CIK 0001783647 · 10% owner MILLENNIUM GROUP MANAGEMENT LLC · CIK 0001446830 · 10% owner ENGLANDER ISRAEL A · CIK 0001017456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 147,731 F16 · price: Represents VWAP of purchases of 1,613 shares of the Company's Common Stock on April 1, 2026 at prices ranging from $34.04 to $34.98. F2 · balance_after: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3 · ownership.nature: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. Read SEC document |
| April 01, 2026 Filed May 15, 2026 20:22 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | PurchaseCommon Stock | 1,161 | $31.53 | $36,607.37 |
DisclosureSEC source: 0001104659-26-062605 · tm2614687-3_4seq1.xml · nonDerivative · entry 13 MILLENNIUM MANAGEMENT LLC · CIK 0001273087 · 10% owner ICS OPPORTUNITIES II LLC · CIK 0001783647 · 10% owner MILLENNIUM GROUP MANAGEMENT LLC · CIK 0001446830 · 10% owner ENGLANDER ISRAEL A · CIK 0001017456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 147,731 F15 · price: Represents VWAP of purchases of 1,161 shares of the Company's Common Stock on April 1, 2026 at prices ranging from $31.52 to $32.50. F2 · balance_after: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3 · ownership.nature: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. Read SEC document |
| March 31, 2026 Filed May 15, 2026 20:22 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | SaleCommon Stock | 87 | $31.52 | $2,742.24 |
DisclosureSEC source: 0001104659-26-062605 · tm2614687-3_4seq1.xml · nonDerivative · entry 12 MILLENNIUM MANAGEMENT LLC · CIK 0001273087 · 10% owner ICS OPPORTUNITIES II LLC · CIK 0001783647 · 10% owner MILLENNIUM GROUP MANAGEMENT LLC · CIK 0001446830 · 10% owner ENGLANDER ISRAEL A · CIK 0001017456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 146,657 F14 · price: Represents sales of 87 shares of the Company's Common Stock on March 31, 2026 at $31.52 per share. F2 · balance_after: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3 · ownership.nature: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. Read SEC document |
| March 31, 2026 Filed May 15, 2026 20:22 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | SaleCommon Stock | 5 | $28.41 | $142.03 |
DisclosureSEC source: 0001104659-26-062605 · tm2614687-3_4seq1.xml · nonDerivative · entry 11 MILLENNIUM MANAGEMENT LLC · CIK 0001273087 · 10% owner ICS OPPORTUNITIES II LLC · CIK 0001783647 · 10% owner MILLENNIUM GROUP MANAGEMENT LLC · CIK 0001446830 · 10% owner ENGLANDER ISRAEL A · CIK 0001017456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 146,657 F13 · price: Represents sales of 5 shares of the Company's Common Stock on March 31, 2026 at $28.4050 per share. F2 · balance_after: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3 · ownership.nature: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. Read SEC document |
| March 31, 2026 Filed May 15, 2026 20:22 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | SaleCommon Stock | 57 | $27.11 | $1,545.54 |
DisclosureSEC source: 0001104659-26-062605 · tm2614687-3_4seq1.xml · nonDerivative · entry 10 MILLENNIUM MANAGEMENT LLC · CIK 0001273087 · 10% owner ICS OPPORTUNITIES II LLC · CIK 0001783647 · 10% owner MILLENNIUM GROUP MANAGEMENT LLC · CIK 0001446830 · 10% owner ENGLANDER ISRAEL A · CIK 0001017456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 146,657 F12 · price: Represents sales of 57 shares of the Company's Common Stock on March 31, 2026 at $27.1147 per share. F2 · balance_after: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3 · ownership.nature: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. Read SEC document |
| March 31, 2026 Filed May 15, 2026 20:22 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | SaleCommon Stock | 1,251 | $25.17 | $31,484.67 |
DisclosureSEC source: 0001104659-26-062605 · tm2614687-3_4seq1.xml · nonDerivative · entry 9 MILLENNIUM MANAGEMENT LLC · CIK 0001273087 · 10% owner ICS OPPORTUNITIES II LLC · CIK 0001783647 · 10% owner MILLENNIUM GROUP MANAGEMENT LLC · CIK 0001446830 · 10% owner ENGLANDER ISRAEL A · CIK 0001017456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 146,657 F11 · price: Represents VWAP of sales of 1,251 shares of the Company's Common Stock on March 31, 2026 at prices ranging from $25.13 to $25.45. F2 · balance_after: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3 · ownership.nature: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. Read SEC document |
| March 31, 2026 Filed May 15, 2026 20:22 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | SaleCommon Stock | 191 | $24.28 | $4,638.30 |
DisclosureSEC source: 0001104659-26-062605 · tm2614687-3_4seq1.xml · nonDerivative · entry 8 MILLENNIUM MANAGEMENT LLC · CIK 0001273087 · 10% owner ICS OPPORTUNITIES II LLC · CIK 0001783647 · 10% owner MILLENNIUM GROUP MANAGEMENT LLC · CIK 0001446830 · 10% owner ENGLANDER ISRAEL A · CIK 0001017456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 146,657 F10 · price: Represents VWAP of sales of 191 shares of the Company's Common Stock on March 31, 2026 at prices ranging from $23.91 to $24.6089. F2 · balance_after: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3 · ownership.nature: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. Read SEC document |
| March 31, 2026 Filed May 15, 2026 20:22 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | PurchaseCommon Stock | 411 | $32.60 | $13,397.04 |
DisclosureSEC source: 0001104659-26-062605 · tm2614687-3_4seq1.xml · nonDerivative · entry 7 MILLENNIUM MANAGEMENT LLC · CIK 0001273087 · 10% owner ICS OPPORTUNITIES II LLC · CIK 0001783647 · 10% owner MILLENNIUM GROUP MANAGEMENT LLC · CIK 0001446830 · 10% owner ENGLANDER ISRAEL A · CIK 0001017456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 146,657 F9 · price: Represents VWAP of purchases of 411 shares of the Company's Common Stock on March 31, 2026 at prices ranging from $32.4343 to $32.91. F2 · balance_after: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3 · ownership.nature: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. Read SEC document |
| March 31, 2026 Filed May 15, 2026 20:22 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | PurchaseCommon Stock | 1,957 | $31.45 | $61,550.00 |
DisclosureSEC source: 0001104659-26-062605 · tm2614687-3_4seq1.xml · nonDerivative · entry 6 MILLENNIUM MANAGEMENT LLC · CIK 0001273087 · 10% owner ICS OPPORTUNITIES II LLC · CIK 0001783647 · 10% owner MILLENNIUM GROUP MANAGEMENT LLC · CIK 0001446830 · 10% owner ENGLANDER ISRAEL A · CIK 0001017456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 146,657 F8 · price: Represents VWAP of purchases of 1,957 shares of the Company's Common Stock on March 31, 2026 at prices ranging from $31.215 to $31.17. F2 · balance_after: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3 · ownership.nature: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. Read SEC document |
| March 31, 2026 Filed May 15, 2026 20:22 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | PurchaseCommon Stock | 186 | $30.48 | $5,668.42 |
DisclosureSEC source: 0001104659-26-062605 · tm2614687-3_4seq1.xml · nonDerivative · entry 5 MILLENNIUM MANAGEMENT LLC · CIK 0001273087 · 10% owner ICS OPPORTUNITIES II LLC · CIK 0001783647 · 10% owner MILLENNIUM GROUP MANAGEMENT LLC · CIK 0001446830 · 10% owner ENGLANDER ISRAEL A · CIK 0001017456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 146,657 F7 · price: Represents VWAP of purchases of 186 shares of the Company's Common Stock on March 31, 2026 at prices ranging from $30.1693 to $30.73. F2 · balance_after: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3 · ownership.nature: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. Read SEC document |
| March 31, 2026 Filed May 15, 2026 20:22 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | PurchaseCommon Stock | 17 | $27.78 | $472.32 |
DisclosureSEC source: 0001104659-26-062605 · tm2614687-3_4seq1.xml · nonDerivative · entry 4 MILLENNIUM MANAGEMENT LLC · CIK 0001273087 · 10% owner ICS OPPORTUNITIES II LLC · CIK 0001783647 · 10% owner MILLENNIUM GROUP MANAGEMENT LLC · CIK 0001446830 · 10% owner ENGLANDER ISRAEL A · CIK 0001017456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 146,657 F6 · price: Represents VWAP of purchases of 17 shares of the Company's Common Stock on March 31, 2026 at prices ranging from $27.525 to $28.405. F2 · balance_after: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3 · ownership.nature: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. Read SEC document |
| March 31, 2026 Filed May 15, 2026 20:22 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | PurchaseCommon Stock | 1,048 | $26.73 | $28,008.74 |
DisclosureSEC source: 0001104659-26-062605 · tm2614687-3_4seq1.xml · nonDerivative · entry 3 MILLENNIUM MANAGEMENT LLC · CIK 0001273087 · 10% owner ICS OPPORTUNITIES II LLC · CIK 0001783647 · 10% owner MILLENNIUM GROUP MANAGEMENT LLC · CIK 0001446830 · 10% owner ENGLANDER ISRAEL A · CIK 0001017456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 146,657 F5 · price: Represents VWAP of purchases of 1,048 shares of the Company's Common Stock on March 31, 2026 at prices ranging from $26.2587 to $27.1994. F2 · balance_after: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3 · ownership.nature: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. Read SEC document |
| March 31, 2026 Filed May 15, 2026 20:22 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | PurchaseCommon Stock | 1,770 | $25.32 | $44,817.99 |
DisclosureSEC source: 0001104659-26-062605 · tm2614687-3_4seq1.xml · nonDerivative · entry 2 MILLENNIUM MANAGEMENT LLC · CIK 0001273087 · 10% owner ICS OPPORTUNITIES II LLC · CIK 0001783647 · 10% owner MILLENNIUM GROUP MANAGEMENT LLC · CIK 0001446830 · 10% owner ENGLANDER ISRAEL A · CIK 0001017456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 146,657 F4 · price: Represents VWAP of purchases of 1,770 shares of the Company's Common Stock on March 31, 2026 at prices ranging from $25.13 to $26.12. F2 · balance_after: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3 · ownership.nature: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. Read SEC document |
| March 31, 2026 Filed May 15, 2026 20:22 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | PurchaseCommon Stock | 616 | $24.69 | $15,206.39 |
DisclosureSEC source: 0001104659-26-062605 · tm2614687-3_4seq1.xml · nonDerivative · entry 1 MILLENNIUM MANAGEMENT LLC · CIK 0001273087 · 10% owner ICS OPPORTUNITIES II LLC · CIK 0001783647 · 10% owner MILLENNIUM GROUP MANAGEMENT LLC · CIK 0001446830 · 10% owner ENGLANDER ISRAEL A · CIK 0001017456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 146,657 F1 · price: Represents volume-weighted average price ("VWAP") of purchases of 616 shares of common stock ("Common Stock"), par value $0.0001 per share, of Sensei Biotherapeutics, Inc. (the "Company") on March 31, 2026 at prices ranging from $23.91 to $24.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting persons will provide full information regarding the number of shares purchased or sold by the reporting person at each separate price within each range represented by a VWAP disclosed herein. F2 · balance_after: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3 · ownership.nature: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. Read SEC document |
| March 30, 2026 Filed May 15, 2026 20:22 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | SaleCommon Stock | 370 | $27.68 | $10,241.60 |
DisclosureSEC source: 0001104659-26-062603 · tm2614687-2_4seq1.xml · nonDerivative · entry 17 MILLENNIUM MANAGEMENT LLC · CIK 0001273087 · 10% owner ICS OPPORTUNITIES II LLC · CIK 0001783647 · 10% owner MILLENNIUM GROUP MANAGEMENT LLC · CIK 0001446830 · 10% owner ENGLANDER ISRAEL A · CIK 0001017456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 145,678 F19 · price: Represents sales of 370 shares of the Company's Common Stock on March 30, 2026 at $27.68 per share. F2 · balance_after: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3 · ownership.nature: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. Read SEC document |
| March 30, 2026 Filed May 15, 2026 20:22 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | SaleCommon Stock | 518 | $25.85 | $13,390.35 |
DisclosureSEC source: 0001104659-26-062603 · tm2614687-2_4seq1.xml · nonDerivative · entry 16 MILLENNIUM MANAGEMENT LLC · CIK 0001273087 · 10% owner ICS OPPORTUNITIES II LLC · CIK 0001783647 · 10% owner MILLENNIUM GROUP MANAGEMENT LLC · CIK 0001446830 · 10% owner ENGLANDER ISRAEL A · CIK 0001017456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 145,678 F18 · price: Represents VWAP of sales of 518 shares of the Company's Common Stock on March 30, 2026 at prices ranging from $25.13 to $26.0734. F2 · balance_after: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3 · ownership.nature: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. Read SEC document |
| March 30, 2026 Filed May 15, 2026 20:22 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | PurchaseCommon Stock | 370 | $27.68 | $10,241.60 |
DisclosureSEC source: 0001104659-26-062603 · tm2614687-2_4seq1.xml · nonDerivative · entry 15 MILLENNIUM MANAGEMENT LLC · CIK 0001273087 · 10% owner ICS OPPORTUNITIES II LLC · CIK 0001783647 · 10% owner MILLENNIUM GROUP MANAGEMENT LLC · CIK 0001446830 · 10% owner ENGLANDER ISRAEL A · CIK 0001017456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 145,678 F17 · price: Represents purchases of 370 shares of the Company's Common Stock on March 30, 2026 at $27.68 per share. F2 · balance_after: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3 · ownership.nature: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. Read SEC document |
| March 30, 2026 Filed May 15, 2026 20:22 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | PurchaseCommon Stock | 1,176 | $26.70 | $31,399.20 |
DisclosureSEC source: 0001104659-26-062603 · tm2614687-2_4seq1.xml · nonDerivative · entry 14 MILLENNIUM MANAGEMENT LLC · CIK 0001273087 · 10% owner ICS OPPORTUNITIES II LLC · CIK 0001783647 · 10% owner MILLENNIUM GROUP MANAGEMENT LLC · CIK 0001446830 · 10% owner ENGLANDER ISRAEL A · CIK 0001017456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 145,678 F16 · price: Represents VWAP of purchases of 1,176 shares of the Company's Common Stock on March 30, 2026 at prices ranging from $26.50 to $26.90. F2 · balance_after: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3 · ownership.nature: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. Read SEC document |
| March 30, 2026 Filed May 15, 2026 20:22 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | PurchaseCommon Stock | 4,995 | $25.99 | $129,820.05 |
DisclosureSEC source: 0001104659-26-062603 · tm2614687-2_4seq1.xml · nonDerivative · entry 13 MILLENNIUM MANAGEMENT LLC · CIK 0001273087 · 10% owner ICS OPPORTUNITIES II LLC · CIK 0001783647 · 10% owner MILLENNIUM GROUP MANAGEMENT LLC · CIK 0001446830 · 10% owner ENGLANDER ISRAEL A · CIK 0001017456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 145,678 F15 · price: Represents VWAP of purchases of 4,995 shares of the Company's Common Stock on March 30, 2026 at prices ranging from $25.50 to $26.48. F2 · balance_after: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3 · ownership.nature: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. Read SEC document |
| March 30, 2026 Filed May 15, 2026 20:22 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | PurchaseCommon Stock | 2,992 | $25.08 | $75,034.57 |
DisclosureSEC source: 0001104659-26-062603 · tm2614687-2_4seq1.xml · nonDerivative · entry 12 MILLENNIUM MANAGEMENT LLC · CIK 0001273087 · 10% owner ICS OPPORTUNITIES II LLC · CIK 0001783647 · 10% owner MILLENNIUM GROUP MANAGEMENT LLC · CIK 0001446830 · 10% owner ENGLANDER ISRAEL A · CIK 0001017456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 145,678 F14 · price: Represents VWAP of purchases of 2,992 shares of the Company's Common Stock on March 30, 2026 at prices ranging from $24.495 to $25.1856. F2 · balance_after: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3 · ownership.nature: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. Read SEC document |
| March 27, 2026 Filed May 15, 2026 20:22 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | SaleCommon Stock | 36 | $27.37 | $985.28 |
DisclosureSEC source: 0001104659-26-062603 · tm2614687-2_4seq1.xml · nonDerivative · entry 11 MILLENNIUM MANAGEMENT LLC · CIK 0001273087 · 10% owner ICS OPPORTUNITIES II LLC · CIK 0001783647 · 10% owner MILLENNIUM GROUP MANAGEMENT LLC · CIK 0001446830 · 10% owner ENGLANDER ISRAEL A · CIK 0001017456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 142,360 F13 · price: Represents VWAP of sales of 36 shares of the Company's Common Stock on March 27, 2026 at prices ranging from $27.2322 to $27.68. F2 · balance_after: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3 · ownership.nature: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. Read SEC document |
| March 27, 2026 Filed May 15, 2026 20:22 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | SaleCommon Stock | 469 | $26.77 | $12,552.88 |
DisclosureSEC source: 0001104659-26-062603 · tm2614687-2_4seq1.xml · nonDerivative · entry 10 MILLENNIUM MANAGEMENT LLC · CIK 0001273087 · 10% owner ICS OPPORTUNITIES II LLC · CIK 0001783647 · 10% owner MILLENNIUM GROUP MANAGEMENT LLC · CIK 0001446830 · 10% owner ENGLANDER ISRAEL A · CIK 0001017456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 142,360 F12 · price: Represents VWAP of sales of 469 shares of the Company's Common Stock on March 27, 2026 at prices ranging from $26.21 to $26.95. F2 · balance_after: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3 · ownership.nature: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. Read SEC document |
| March 27, 2026 Filed May 15, 2026 20:22 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | PurchaseCommon Stock | 294 | $28.13 | $8,270.25 |
DisclosureSEC source: 0001104659-26-062603 · tm2614687-2_4seq1.xml · nonDerivative · entry 9 MILLENNIUM MANAGEMENT LLC · CIK 0001273087 · 10% owner ICS OPPORTUNITIES II LLC · CIK 0001783647 · 10% owner MILLENNIUM GROUP MANAGEMENT LLC · CIK 0001446830 · 10% owner ENGLANDER ISRAEL A · CIK 0001017456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 142,360 F11 · price: Represents VWAP of purchases of 294 shares of the Company's Common Stock on March 27, 2026 at prices ranging from $28.10 to $28.60. F2 · balance_after: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3 · ownership.nature: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. Read SEC document |
| March 27, 2026 Filed May 15, 2026 20:22 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | PurchaseCommon Stock | 4,384 | $27.28 | $119,606.92 |
DisclosureSEC source: 0001104659-26-062603 · tm2614687-2_4seq1.xml · nonDerivative · entry 8 MILLENNIUM MANAGEMENT LLC · CIK 0001273087 · 10% owner ICS OPPORTUNITIES II LLC · CIK 0001783647 · 10% owner MILLENNIUM GROUP MANAGEMENT LLC · CIK 0001446830 · 10% owner ENGLANDER ISRAEL A · CIK 0001017456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 142,360 F10 · price: Represents VWAP of purchases of 4,384 shares of the Company's Common Stock on March 27, 2026 at prices ranging from $26.9750 to $27.68. F2 · balance_after: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3 · ownership.nature: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. Read SEC document |
| March 27, 2026 Filed May 15, 2026 20:22 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | PurchaseCommon Stock | 10,643 | $26.29 | $279,839.59 |
DisclosureSEC source: 0001104659-26-062603 · tm2614687-2_4seq1.xml · nonDerivative · entry 7 MILLENNIUM MANAGEMENT LLC · CIK 0001273087 · 10% owner ICS OPPORTUNITIES II LLC · CIK 0001783647 · 10% owner MILLENNIUM GROUP MANAGEMENT LLC · CIK 0001446830 · 10% owner ENGLANDER ISRAEL A · CIK 0001017456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 142,360 F9 · price: Represents VWAP of purchases of 10,643 shares of the Company's Common Stock on March 27, 2026 at prices ranging from $25.9197 to $26.88. F2 · balance_after: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3 · ownership.nature: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. Read SEC document |
| March 26, 2026 Filed May 15, 2026 20:22 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | SaleCommon Stock | 1,274 | $28.69 | $36,548.77 |
DisclosureSEC source: 0001104659-26-062603 · tm2614687-2_4seq1.xml · nonDerivative · entry 6 MILLENNIUM MANAGEMENT LLC · CIK 0001273087 · 10% owner ICS OPPORTUNITIES II LLC · CIK 0001783647 · 10% owner MILLENNIUM GROUP MANAGEMENT LLC · CIK 0001446830 · 10% owner ENGLANDER ISRAEL A · CIK 0001017456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 131,370 F8 · price: Represents VWAP of sales of 1,274 shares of the Company's Common Stock on March 26, 2026 at prices ranging from $28.07 to $28.7651. F2 · balance_after: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3 · ownership.nature: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. Read SEC document |
| March 26, 2026 Filed May 15, 2026 20:22 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | SaleCommon Stock | 583 | $26.88 | $15,670.87 |
DisclosureSEC source: 0001104659-26-062603 · tm2614687-2_4seq1.xml · nonDerivative · entry 5 MILLENNIUM MANAGEMENT LLC · CIK 0001273087 · 10% owner ICS OPPORTUNITIES II LLC · CIK 0001783647 · 10% owner MILLENNIUM GROUP MANAGEMENT LLC · CIK 0001446830 · 10% owner ENGLANDER ISRAEL A · CIK 0001017456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 131,370 F7 · price: Represents VWAP of sales of 583 shares of the Company's Common Stock on March 26, 2026 at prices ranging from $26.68 to $27.4650. F2 · balance_after: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3 · ownership.nature: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. Read SEC document |
| March 26, 2026 Filed May 15, 2026 20:22 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | PurchaseCommon Stock | 1,025 | $29.98 | $30,728.27 |
DisclosureSEC source: 0001104659-26-062603 · tm2614687-2_4seq1.xml · nonDerivative · entry 4 MILLENNIUM MANAGEMENT LLC · CIK 0001273087 · 10% owner ICS OPPORTUNITIES II LLC · CIK 0001783647 · 10% owner MILLENNIUM GROUP MANAGEMENT LLC · CIK 0001446830 · 10% owner ENGLANDER ISRAEL A · CIK 0001017456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 131,370 F6 · price: Represents VWAP of purchases of 1,025 shares of the Company's Common Stock on March 26, 2026 at prices ranging from $29.79 to $30.105. F2 · balance_after: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3 · ownership.nature: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. Read SEC document |
| March 26, 2026 Filed May 15, 2026 20:22 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | PurchaseCommon Stock | 2,601 | $28.85 | $75,048.99 |
DisclosureSEC source: 0001104659-26-062603 · tm2614687-2_4seq1.xml · nonDerivative · entry 3 MILLENNIUM MANAGEMENT LLC · CIK 0001273087 · 10% owner ICS OPPORTUNITIES II LLC · CIK 0001783647 · 10% owner MILLENNIUM GROUP MANAGEMENT LLC · CIK 0001446830 · 10% owner ENGLANDER ISRAEL A · CIK 0001017456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 131,370 F5 · price: Represents VWAP of purchases of 2,601 shares of the Company's Common Stock on March 26, 2026 at prices ranging from $28.7072 to $29.51. F2 · balance_after: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3 · ownership.nature: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. Read SEC document |
| March 26, 2026 Filed May 15, 2026 20:22 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | PurchaseCommon Stock | 1,327 | $27.95 | $37,085.27 |
DisclosureSEC source: 0001104659-26-062603 · tm2614687-2_4seq1.xml · nonDerivative · entry 2 MILLENNIUM MANAGEMENT LLC · CIK 0001273087 · 10% owner ICS OPPORTUNITIES II LLC · CIK 0001783647 · 10% owner MILLENNIUM GROUP MANAGEMENT LLC · CIK 0001446830 · 10% owner ENGLANDER ISRAEL A · CIK 0001017456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 131,370 F4 · price: Represents VWAP of purchases of 1,327 shares of the Company's Common Stock on March 26, 2026 at prices ranging from $27.70 to $28.4163. F2 · balance_after: In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. F3 · ownership.nature: The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.